A multicenter study of Vitestro’s autonomous phlebotomy system, Aletta, points to a shift in how clinical labs approach blood collection. The ADOPT trial, conducted across outpatient settings in the Netherlands with additional US data, evaluated performance, safety, and patient experience in routine practice. The research was outlined in an April 10 article in the journal […]
May 4, 2026, Intelligence: Late-Breaking Lab News
- By Janette Wider
- > From the Volume XXXIII, No. 6 - May 04, 2026 Issue
- Tags: ADOPT trial, adverse events, Aletta, autonomous phlebotomy, Bio-Rad Laboratories, Celsee, Christopher “Dirk” Keene MD PhD, clinical chemistry, Crouse Health, Curio Bioscience, difficult-access, G2 Intelligence, George C. Hill PhD, hemolysis, high-BMI, John Stark, Josh Stahl, LabCorp, Neil Kennedy, pre-analytical phase, Quantum-Si, RareCyte, redraws, Resolve Biosciences, robotic phlebotomy, scalable growth, Singular Diagnostics, specimen quality, Takara Bio USA, the dark report, University of California San Diego School of Medicine, Vanderbilt Health, Vitestro
